

Amorphous Drugs

Marzena Rams-Baron • Renata Jachowicz •
Elena Boldyreva • Deliang Zhou •
Witold Jamroz • Marian Paluch

Amorphous Drugs

Benefits and Challenges

 Springer

Marzena Rams-Baron
Institute of Physics
University of Silesia
Chorzów, Poland

Renata Jachowicz
Chair of Pharmaceutical Technology and
Biopharmaceutics, Faculty of Pharmacy
Jagiellonian University - Medical College
Kraków, Poland

Elena Boldyreva
Institute of Solid State Chemistry and
Mechanochemistry, Siberian Branch
of the Russian Academy of Sciences
Novosibirsk State University
Novosibirsk, Russian Federation

Deliang Zhou
AbbVie
North Chicago, USA

Witold Jamroz
Chair of Pharmaceutical Technology and
Biopharmaceutics, Faculty of Pharmacy
Jagiellonian University - Medical College
Kraków, Poland

Marian Paluch
Institute of Physics
University of Silesia
Chorzów, Poland

ISBN 978-3-319-72001-2 ISBN 978-3-319-72002-9 (eBook)
<https://doi.org/10.1007/978-3-319-72002-9>

Library of Congress Control Number: 2017962001

© Springer International Publishing AG 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer International Publishing AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Acknowledgment

The authors, Marzena Rams-Baron, Renata Jachowicz, Witold Jamroz and Marian Paluch are grateful for the financial support received within the Project No. 2015/16/W/NZ7/00404 (Symfonia 3) from the Polish National Science Centre.

Contents

1	Why Amorphous Drugs?	1
	References	6
2	Order vs. Disorder in the Solid State	9
2.1	Perfect Order (Crystalline Materials)	9
2.1.1	Periodic Structures	9
2.1.2	Aperiodic Structures	9
2.2	Perfect Disorder (Amorphous Materials)	15
2.2.1	Radial Distribution Function	16
2.2.2	Voronoi-Dirichlet Polyhedra (VDP)	19
2.2.3	Random Close Packing (RCP)	20
2.2.4	Polyhedral Networks	22
2.2.5	Molecular Glasses and Hybrid Materials	25
2.2.6	Polyamorphism	27
2.3	Between Order and Disorder	28
	References	32
3	Amorphous Drug Solubility and Absorption Enhancement	41
3.1	Introduction	41
3.2	The Strategies in Drug Solubility Improvement	43
3.2.1	Amorphous Pharmaceuticals	44
3.2.2	Amorphous Solids	45
3.2.3	Solid Dispersions	46
3.3	Solubility and Dissolution Strategy for Bioavailability Improvement	49
3.4	Case Studies	59
3.5	Conclusion	64
	References	65

4 Amorphous Drug Preparation Methods	69
4.1 Hot-Melt Extrusion	69
4.2 Technology of Three Dimensional Printing	74
4.3 Manufacturing Methods Based on Solvent Evaporation	77
4.3.1 Freeze-Drying	77
4.3.2 Spray-Drying	79
4.3.3 Supercritical Fluid Technology (SCF)	83
4.3.4 Electrospinning and Electrospraying	85
4.3.5 Thin Films Manufacturing	87
4.4 Preparing Amorphous Samples by Dehydration of Crystal Hydrates	89
4.5 Preparing Amorphous Samples by Mechanical Treatment	92
References	95
5 Physical Instability: A Key Problem of Amorphous Drugs	107
5.1 Understanding Crystallization from Amorphous State	107
5.1.1 Thermodynamic Contributions	110
5.1.2 Kinetic Contributions	113
5.1.3 Other Contributions	116
5.1.4 Implications for Drug Stability	118
5.2 How to Improve the Physical Stability of Amorphous APIs?	127
5.2.1 Amorphous Solid Dispersions	127
5.2.2 Binary Drug-Drug Mixtures	136
5.2.3 Spatially Confined Systems	140
5.3 The Stability of Amorphous Drugs Under High Pressure Condition	145
References	148
6 Amorphous Drug Formulation	159
6.1 Introduction	159
6.2 Understanding Oral Bioavailability Enhancement	161
6.2.1 The Rediscovery of Liquid-Liquid Phase Separation (LLPS)	161
6.2.2 Formation of Amorphous Drug Nanoparticles	169
6.2.3 The Keys	174
6.3 The Major Manufacturing Technologies for Amorphous Solid Dispersions	174
6.3.1 Hot Melt Extrusion (HME)	174
6.3.2 Spray Drying	180
6.4 Considerations for Drug Product Development	185
6.4.1 Pharmaceutical Properties	185
6.4.2 Physical Stability of Amorphous Forms and Amorphous Solid Dispersions	187
6.4.3 Biopharmaceutical Considerations	188
6.4.4 Process Considerations	190

6.5	Rational Formulation Design and Product Development	196
6.5.1	Selecting the Carrier Polymer	197
6.5.2	Optimize Oral Bioavailability of ASD	202
6.5.3	In Vitro and In Vivo Characterization	209
6.5.4	Process Development	212
6.6	Concluding Remarks	217
	References	217
Index	225